dermatology
Autoimmune diseases

Bullous pemphigoid risk seen with DPP-4 inhibitors in diabetes


The use of dipeptidyl peptidase 4 (DPP-4) inhibitors, especially vildagliptin, in patients with diabetes continues to be associated with an increased risk of bullous pemphigoid. In the most recent evidence, a large retrospective case-control study found patients with diabetes and bullous pemphigoid were more likely to be treated with DPP-4 inhibitors (39%) than patients with ...

Already a member?

Enter your email to keep reading.


OR